Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.
Best Pract Res Clin Rheumatol
; 32(6): 803-812, 2018 12.
Article
in En
| MEDLINE
| ID: mdl-31427056
ABSTRACT
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role of various large-vessel imaging modalities to help confirm a diagnosis of GCA. Systemic corticosteroids (CS) remain the mainstay of treatment for both PMR and GCA, yet both relapses and CS-related side effects are common. Recent research has demonstrated efficacy of certain biologic agents in these diseases, with particular emphasis on the role of interleukin-6 (IL-6) blockade in GCA. This chapter discusses the latest updates on the diagnosis and treatment of PMR/GCA, with an emphasis on clinical care.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polymyalgia Rheumatica
/
Giant Cell Arteritis
/
Adrenal Cortex Hormones
Limits:
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Best Pract Res Clin Rheumatol
Journal subject:
REUMATOLOGIA
Year:
2018
Document type:
Article